[go: up one dir, main page]

CL2009001766A1 - Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica. - Google Patents

Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.

Info

Publication number
CL2009001766A1
CL2009001766A1 CL2009001766A CL2009001766A CL2009001766A1 CL 2009001766 A1 CL2009001766 A1 CL 2009001766A1 CL 2009001766 A CL2009001766 A CL 2009001766A CL 2009001766 A CL2009001766 A CL 2009001766A CL 2009001766 A1 CL2009001766 A1 CL 2009001766A1
Authority
CL
Chile
Prior art keywords
composition
oral administration
solid pharmaceutical
preparing
surfactant
Prior art date
Application number
CL2009001766A
Other languages
English (en)
Inventor
Jacob Hendrik Beijnen
Johannes Moes
Bastiaan Nuijen
Johannes Henricus Matthias Schellens
Original Assignee
Slotervaart Participaties Bv
Stichting Het Nederlands Kanker Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0716591A external-priority patent/GB0716591D0/en
Application filed by Slotervaart Participaties Bv, Stichting Het Nederlands Kanker Inst filed Critical Slotervaart Participaties Bv
Publication of CL2009001766A1 publication Critical patent/CL2009001766A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSICIONES FARMACÉUTICAS SÓLIDAS CON TAXANO PARA ADMINISTRACIÓN ORAL QUE COMPRENDEN UN TAXANO SUSTANCIALMENTE AMARFO, UN PORTADOR Y UN TENSOACTIVO. TAMBIÉN SE INCLUYEN MÉTODOS DE PREPARACIÓN DE LA COMPOSICIÓN Y USOS DE LA COMPOSICIÓN.
CL2009001766A 2007-08-24 2009-08-24 Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica. CL2009001766A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95776407P 2007-08-24 2007-08-24
GB0716591A GB0716591D0 (en) 2007-08-24 2007-08-24 Composition
PCT/GB2008/002854 WO2009027644A2 (en) 2007-08-24 2008-08-22 Composition

Publications (1)

Publication Number Publication Date
CL2009001766A1 true CL2009001766A1 (es) 2010-07-09

Family

ID=39985965

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001766A CL2009001766A1 (es) 2007-08-24 2009-08-24 Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.

Country Status (11)

Country Link
US (1) US20110207804A1 (es)
EP (1) EP2190413B1 (es)
KR (1) KR101544498B1 (es)
AR (1) AR073123A1 (es)
AU (1) AU2008291930B2 (es)
CA (1) CA2696622C (es)
CL (1) CL2009001766A1 (es)
IL (1) IL204115B (es)
MX (1) MX2010002179A (es)
WO (1) WO2009027644A2 (es)
ZA (1) ZA201001304B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
CA2613889A1 (en) 2005-06-08 2006-12-14 Centocor, Inc. A cellular therapy for ocular degeneration
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
CA3114827C (en) 2007-07-31 2023-09-05 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic endocrine
US9089544B2 (en) * 2007-08-24 2015-07-28 Slotervaart Participaties Bv Composition
CA2954431C (en) 2007-11-27 2021-08-24 Lifescan, Inc. Differentiation of human embryonic stem cells to pancreatic cells
RU2551772C2 (ru) 2008-02-21 2015-05-27 Сентокор Орто Байотек Инк. Способы, поверхностно-модифицированные носители и композиции для иммобилизации, культивирования и открепления клеток
AU2009267137A1 (en) 2008-06-30 2010-01-07 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
MX2011004563A (es) 2008-10-31 2011-06-01 Centocor Ortho Biotech Inc Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico.
MX2011004565A (es) 2008-10-31 2011-07-28 Centocor Ortho Biotech Inc Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico.
BRPI0921996A2 (pt) 2008-11-20 2015-08-18 Centocor Ortho Biotech Inc Métodos e composições para cultura e ligação de células em substratos planos.
EP3260534A1 (en) 2008-11-20 2017-12-27 Janssen Biotech, Inc. Pluripotent stem cell culture on micro-carriers
KR101785626B1 (ko) 2009-07-20 2017-10-16 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
EP2456862A4 (en) 2009-07-20 2013-02-27 Janssen Biotech Inc DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS
KR101786735B1 (ko) 2009-07-20 2017-10-18 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
DK2519231T3 (en) * 2009-10-01 2017-06-26 Janssen Pharmaceutica Nv Proteasome inhibitors for the treatment of cancer
PH12012501254A1 (en) 2009-12-23 2012-11-05 Janssen Biotech Inc Differentiation of human embryonic stem cells
BR112012017761A2 (pt) 2009-12-23 2015-09-15 Centocor Ortho Biotech Inc diferenciação das células-tronco embrionárias humanas
EP2525783A1 (en) * 2010-01-18 2012-11-28 Cephalon France Improved oral lysophilisates containing pvp/va
US9969981B2 (en) 2010-03-01 2018-05-15 Janssen Biotech, Inc. Methods for purifying cells derived from pluripotent stem cells
RU2663339C1 (ru) 2010-05-12 2018-08-03 Янссен Байотек, Инк. Дифференцирование эмбриональных стволовых клеток человека
KR101836850B1 (ko) 2010-08-31 2018-03-09 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
JP6133776B2 (ja) 2010-08-31 2017-05-24 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞の分化
CA2809300A1 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
AU2012355698B2 (en) 2011-12-22 2018-11-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
RU2018128383A (ru) 2012-03-07 2019-03-14 Янссен Байотек, Инк. Среда определенного состава для размножения и обновления плюрипотентных стволовых клеток
RU2018108850A (ru) 2012-06-08 2019-02-26 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в панкреатические эндокринные клетки
WO2014078576A2 (en) * 2012-11-14 2014-05-22 Abon Pharmaceuticals, Llc Oral transmucosal drug delivery system
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
SG10201707811XA (en) 2012-12-31 2017-11-29 Janssen Biotech Inc Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
EP4039798A1 (en) 2012-12-31 2022-08-10 Janssen Biotech, Inc. Suspension and clustering of human pluripotent cells
MX2015008577A (es) 2012-12-31 2015-09-07 Janssen Biotech Inc Cultivo de celulas madre embrionarias humanas en la interfase aire-liquido para la diferenciacion en celulas endocrinas pancreaticas.
WO2015152433A1 (en) * 2014-03-31 2015-10-08 Hanmi Pharm. Co., Ltd. Amorphous solid dispersion comprising paclitaxel, tablet comprising the same, and method for preparing the same
KR102162138B1 (ko) 2014-05-16 2020-10-06 얀센 바이오테크 인코포레이티드 췌장 내분비 세포에서 mafa 발현을 향상시키기 위한 소분자의 용도
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
TWI833710B (zh) 2017-10-06 2024-03-01 香港商慧源香港創新有限公司 高單位含量口服型紫杉烷組合物及方法
PE20220250A1 (es) 2018-12-21 2022-02-16 Modra Pharmaceuticals B V Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma
CA3124319C (en) * 2018-12-21 2023-07-04 Modra Pharmaceuticals B.V. Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
GB202201935D0 (en) 2022-02-14 2022-03-30 Modra Pharmaceuticals B V Methods and compositions for treating cancer in taxane-resistant patients
US20250235424A1 (en) * 2022-03-08 2025-07-24 Webiotree Co., Ltd Pharmaceutical composition containing docetaxel or pharmaceutically acceptable salt thereof and preparation method therefor
KR102849835B1 (ko) 2022-06-29 2025-08-27 주식회사 나노메디팜 다중 작용 기전을 가지는 초미립 크기의 항암 약물이 탑재된 나노 약물전달 플랫폼, 이를 포함하는 약제학적 조성물 및 그 제조 방법
EP4385507A1 (en) 2022-12-13 2024-06-19 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610317B2 (en) * 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
ATE312601T1 (de) 1999-05-27 2005-12-15 Acusphere Inc Poröse arzneistoffmatrizen und deren herstellungsverfahren
US20080305173A1 (en) * 2001-07-31 2008-12-11 Beuford Arlie Bogue Amorphous drug beads
US8071133B2 (en) * 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
CA2470826A1 (en) * 2001-12-20 2003-07-03 Bristol-Myers Squibb Company Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
AU2003256157A1 (en) * 2002-08-05 2004-02-23 Dsm Ip Assets B.V. Oral dosage forms of water insoluble drugs and methods of making the same
KR100508518B1 (ko) * 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
WO2006026592A2 (en) * 2004-08-27 2006-03-09 Spherics, Inc. Oral administration of poorly absorbed drugs, methods and compositions related thereto
BRPI0608173A2 (pt) * 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
WO2008118754A2 (en) * 2007-03-23 2008-10-02 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods for making the same

Also Published As

Publication number Publication date
HK1144390A1 (en) 2011-02-18
IL204115B (en) 2019-05-30
KR20100044237A (ko) 2010-04-29
US20110207804A1 (en) 2011-08-25
MX2010002179A (es) 2010-04-27
AU2008291930A1 (en) 2009-03-05
EP2190413B1 (en) 2015-01-28
WO2009027644A3 (en) 2009-12-17
WO2009027644A2 (en) 2009-03-05
WO2009027644A8 (en) 2009-04-30
EP2190413A2 (en) 2010-06-02
KR101544498B1 (ko) 2015-08-17
CA2696622A1 (en) 2009-03-05
ZA201001304B (en) 2013-08-28
CA2696622C (en) 2016-07-19
AU2008291930B2 (en) 2014-04-17
AR073123A1 (es) 2010-10-13

Similar Documents

Publication Publication Date Title
CL2009001766A1 (es) Composicion farmaceutica solida para administracion oral que comprende: un taxano sustancialmente amorfo definido, un portador hidrofilico definido y un tensoactivo definido; metodo para preparar la composicion; y su uso para tratar una enfermedad neoplasica.
ECSP12011935A (es) Triazolopiridinas
AR116052A2 (es) Forma cristalina de clorhidrato de (-)-(1r,2r)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol
AR052238A1 (es) Formulacion de tabletas estables
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
ECSP10010295A (es) Formulacion de anticuerpo
CO6331297A2 (es) Composiciones adyuvantes novedosas
HN2004000490A (es) Procedimiento para la preparacion de una composicion farmaceutica solida administrable oralmente
CO6720961A2 (es) Imidazopiridazinas sustituidas
DOP2014000133A (es) Triazolopiridinas sustituidas
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
BRPI0610359B8 (pt) compostos de diaril-hidantoína, suas composições farmacêuticas e sais farmaceuticamente aceitáveis
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
CL2008001103A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-b]piridin-corboxamidas y [1,2,3]triazolo[4,5-d]pirimidin-carboxamidas, inhibidores de megl y faah; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de dolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metabolico, dislipidemia, entre otros.
ECSP12012338A (es) Triazolopiridinas sustituidas
CL2011000935A1 (es) Composicion farmaceutica que comprende acetaminofeno y un material de tramadol complejo, que exhibe una liberacion sostenida y coordinada a traves de una capa de liberacion sostenida y otra de liberacion inmediata; metodo de preparacion;y el uso de un material complejo de tramadol y acetaminofeno para preparar un medicamento para el tratamiento del dolor.
GT200800145A (es) Una composicion solida de taxano liofilizada, un procedimiento para preparar dicha composicion solida, una formulacion farmaceutica y un conjunto (kit) de dicha formulacion
ECSP13013011A (es) Triazolopiridinas
DOP2010000331A (es) Formulacion de medicamento solida con liberacion retardada
AR047928A1 (es) Derivados de tetrahidropiridoindol
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
ECSP066715A (es)
HN2006014095A (es) Forma cristalina ortorrombica del maleato de asenapina
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol